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Abstract
Background: Chlamydia pneumoniae infection has been detected by serological methods, but PCR
is gaining more interest. A number of different PCR assays have been developed and some are used
in combination with serology for diagnosis. Real-time PCR could be an attractive new PCR method;
therefore it must be evaluated and compared to conventional PCR methods.
Results: We compared the performance of a newly developed real-time PCR with a conventional
PCR method for detection of C. pneumoniae. The PCR methods were tested on reference samples
containing C. pneumoniae DNA and on 136 nasopharyngeal samples from patients with a chronic
cough. We found the same detection limit for the two methods and that clinical performance was
equal for the real-time PCR and for the conventional PCR method, although only three samples
tested positive. To investigate whether the low prevalence of C. pneumoniae among patients with a
chronic cough was caused by suboptimal PCR efficiency in the samples, PCR efficiency was
determined based on the real-time PCR. Seventeen of twenty randomly selected clinical samples
had a similar PCR efficiency to samples containing pure genomic C. pneumoniae DNA.
Conclusions: These results indicate that the performance of real-time PCR is comparable to that
of conventional PCR, but that needs to be confirmed further. Real-time PCR can be used to
investigate the PCR efficiency which gives a rough estimate of how well the real-time PCR assay
works in a specific sample type. Suboptimal PCR efficiency of PCR is not a likely explanation for the
low positivity rate of C. pneumoniae in patients with a chronic cough.
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Background
C. pneumoniae causes upper respiratory tract infections,
and in some studies it accounts for 6–10% of community-
acquired pneumonia [1]. Seroprevalence among adults is
40–70%, increasing with age, indicating that most people
are exposed at least once and that reinfections are com-
mon [2]. C. pneumoniae is the microorganism that most
commonly is associated with the inflammation seen in
atherosclerosis [3].
C. pneumoniae infection has been detected by serological
methods but PCR is currently viewed as an advantageous
alternative since it detects the presence of the DNA of the
organism. This allows for an early and clinically relevant
diagnosis in contrast to the detection of C. pneumoniae
specific antibodies that develop late in the course of the
infection. Today, there is no accepted gold standard for
PCR detection of C. pneumoniae, but as a start, guidelines
for standardising C. pneumoniae assays have been pub-
lished [4]. Most laboratories use in-house PCR assays and
DNA purification procedures. Real-time quantitative PCR
in the Lightcycler is a new option among the many PCR
assays and it may become a method of choice as it is fast
and provides a quantitative measure. This is advantageous
in a clinical setting because it allows fast diagnosis and
thus fast treatment with relevant antibiotics. Furthermore,
the quantitative measure could possibly be used to assess
the response to treatment or to assess the state of infec-
tion; active infection versus chronic infection.
The lack of standardisation of PCR methods has been in-
vestigated in three recent studies [5–7]. These studies
found strikingly different results when comparing several
PCR methods. The inconsistent results were explained by
the use of different DNA extraction methods, different
thermal cyclers and differences in number of and/or ho-
mogeneity of replicates. Contradicting C. pneumoniae PCR
results have also been explained by the fact that C. pneu-
moniae is often present in very low numbers because the
infections tend to be chronic and low-grade [8]. Even
though most assays have very good detection limits the
fact that they are often used at DNA concentrations near
their detection limit can pose problems. At low DNA con-
centrations detection/non-detection is more susceptible
to inhibitors because inhibition adds further to the statis-
tical uncertainty already present at the detection limit (i.e.
it is only possible to detect 1 copy of DNA in a fraction of
experiments, because the particle distribution is expected
to follow Poisson statistics). Therefore, it is necessary to
test PCR methods for their performance in different situa-
tions and sample types.
The aim of this study was to compare a newly developed
real-time quantitative PCR in the Lightcycler for detection
of C. pneumoniae[9] with an established conventional PCR
assay used in another laboratory [10,11] to see whether
results obtained with the two methods correlate. In the
real-time PCR the pmp4 gene is target and in the conven-
tional PCR it is the 16S rRNA gene. PCR's were performed
in the laboratories where they were developed. The limit
of detection and performance on clinical specimens were
compared and advantages and disadvantages of the meth-
ods are discussed. PCR efficiency was determined by the
real-time PCR method in a random selection of the clini-
cal samples to test whether inhibitors were present.
Results and discussion
Reference samples: comparison of the two PCR methods
C. pneumoniae-infected HeLa cells were Proteinase K-treat-
ed and a serial four-fold dilution series was prepared with
concentrations near and past the detection limit for both
PCR methods used. These reference samples were tested
with a real-time PCR and a conventional PCR both specif-
ic for C. pneumoniae (see table 1 for sample volumes). The
results obtained from the reference samples with the two
PCR methods are shown in table 2. Samples were blinded
prior to analysis, to avoid experimentator-induced bias.
Both PCR methods correctly identified the five first sam-
ples in the dilution series, and no false positives were ob-
served. In the conventional PCR (method 2) it is an
advantage that a higher template volume can be used,
which might make it possible to detect lower C. pneumo-
niae concentrations. This is not possible for the real-time
PCR method (method 1) as the capillaries limit the reac-
tion volume to 20 µl. In conclusion, the two PCR methods
had the same limit of detection. We avoided using inclu-
sion-forming units (IFU) as a measure of sensitivity be-
cause it is probably not very informative as different
culture systems may vary considerably and because the
determination procedure, which involves cultivation and
counting under a microscope, can be operator dependent
[8]. Measuring DNA concentration with a spectrometer is
less operator dependent and is therefore probably easier
to compare between laboratories. Furthermore, IFU only
measures the number of viable EB in a preparation, it does
not account for RB and dead EB, which also contain ge-
nomic DNA amplifiable by PCR.
Table 1: Sample volumes used in the two PCR methods
PCR method
Sample type
Method 1 Method 2
Standard samples 2 µl-
Reference samples 6.8 µl 10 µl
Clinical samples 2 µl 10 µlBMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
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Determination of PCR efficiency in the reference and 
standard samples with real-time PCR
When performing quantitative real-time PCR, it is as-
sumed that the PCR efficiency of the standard samples is
the same as that of the unknown samples. This is the basis
for the calculations made. Therefore, it is important to de-
termine the efficiency in both standards samples and un-
known samples. PCR efficiency depends e.g. on inhibition
in the sample, how well primers and probes are designed,
and how well the PCR conditions are optimised. PCR effi-
ciency was determined in the reference samples described
above and in standard samples. The standard samples
were a 10-fold dilution series of purified genomic C.
pneumoniae DNA with known concentrations. Threshold
cycles obtained with the real-time PCR for duplicates of
the reference and standard samples were plotted against
log to the concentration of the samples (log to the concen-
tration: arbitrary numbers with four-fold difference for
the reference samples, as concentrations were unknown)
(fig. 1). Two straight lines were drawn and the slopes were
determined by linear regression to be -3.848 (standard er-
ror = 0.259) for the reference samples and -3.144 (stand-
ard error = 0.065) for the standard samples. The two
slopes were found to be significantly different (z = 2.64, P
= 0.008). Efficiency is derived from the idealized function
for the amount of PCR product formed: N = N0 ×  E n,
where N is number of amplified molecules, N0 is the ini-
tial number of molecules, n is the number of amplifica-
tion cycles and E is the efficiency which is ideally 2. The
standard curves are derived from the function described
above: n = -(1/log E) * log N0 + (log N/log E). Therefore,
the slope of the line equals -(1/ log E) and the efficiency
can be calculated from the slope. From the slopes the effi-
ciency of the real-time PCR in the reference samples was
determined to be 1.82 and in the standard samples to be
2.08. The fact that the efficiency is a little larger than 2 is
probably caused by the linear regression analysis which
does not take into account that the efficiency can maxi-
mally be 2. Because of the difference in efficiency between
reference and standard samples an inaccuracy in the deter-
mined concentration of the reference samples is present.
As the efficiency in the reference samples is lower, the con-
centration determined on basis of the standard samples
will be an underestimation. This is seen in table 2, as it
would be highly unlikely to be able to determine the low-
est concentration 0.05 copies/µl if it was not an underes-
timation caused by different efficiencies. The
underestimation factor can be estimated for each cycle
number. At cycle number 30 and with the described dif-
ference in efficiency the concentration would be underes-
timated 23-fold (see fig. 2). Differences in efficiency of
PCR can be caused by several factors e.g. inhibitors and
storage of the sample, but different batches of primers,
probes and enzymes might also influence the efficiency.
The DNA for the reference samples was released by Protei-
nase K treatment only with no subsequent purification;
therefore inhibitors might have been present. Further-
more, as a larger volume of reference sample (6.8 µl) than
standard sample (2 µl) was used, this could increase inhi-
bition. On the other hand, the amplification efficiency ap-
peared to be identical for all dilutions as indicated by the
regression line, so inhibition from the sample preparation
might not be the explanation; the reference samples had
been stored in polypropylene tubes for more than a
month before analysis, and as DNA binds to polypropyl-
ene [12], this could also affect the efficiency observed as
this effect alters the DNA concentrations especially in the
dilute samples [12].
Clinical samples: comparison of the two PCR methods
Nasopharyngeal aspirates were previously obtained from
patients with chronic cough [9] and DNA was released
with Chelex 100. A selection of 136 clinical samples was
used. The results obtained from the clinical samples with
the two PCR methods are shown in table 3. Method 1
found three of 136 samples to be positive and method 2
found the same three samples to be positive, and both
methods found the rest of the samples negative. There-
fore, there seems to be good concordance between the two
PCR methods, but more samples are needed to confirm
this. The three patients found positive for C. pneumoniae
by PCR by both methods were C. pneumoniae IgM posi-
tive. No PCR negative patients were found to be IgM pos-
itive. Therefore, in this study, PCR correlates with the IgM
positivity, meaning that even a small amount of C. pneu-
Table 2: Reference samples analysed with the two PCR assays. * 
The unit of the numbers is copies/µl and the numbers are the 
mean of two measurements from two different runs. # The dilu-
tion series is serial and four-fold. Dilution no. 1 has the highest 
concentration and dilution no. 10 has the lowest concentration. 
Method 1 is the real-time PCR and method 2 is the conventional 
PCR.
PCR method 1 2
Detection probe set* gel
Dilution no. #
1 (high) 76.60 +
27 . 8 6 +
32 . 3 5 +
40 . 6 3 +
50 . 0 5 +
60 . 0 0 -
70 . 0 0 -
80 . 0 0 -
90 . 0 0 -
10 (low) 0.00 -
11 (NK) 0.00 -BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
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moniae DNA in samples (table 3) may reflect an infection
capable of initiating an immune response. This could be
because the clinical samples are from patients with chron-
ic and thereby long-lasting cough. The infection they have
does probably not display high bacterial loads, but more
likely it is an infection with a low load of C. pneumoniae.
In order to assess whether the positivity rate was underes-
timated due to suboptimal efficiency of the real-time PCR,
we performed efficiency analyses on the three positive
clinical specimens and a random selection of negative
clinical samples. Even though there is concordance be-
tween PCR and IgM results, it is believed that IgM may not
be present if it is a reinfection [13]. Therefore it is possible
that PCR is positive when IgM is not.
Spiked clinical samples: determination of PCR efficiency 
by real-time PCR
The efficiency of real-time PCR in the positive clinical
sample with the highest C. pneumoniae DNA concentra-
tion (no. 133) was determined as described above and
compared to the efficiency for the standard samples (fig.
1). A dilution series was prepared of sample 133 and the
threshold cycles determined for duplicates (dilutions: 5,
10, 15, 20, 100 and 1000 times). The slope of the line (fig.
1) was -3.237 (standard error = 0.158) indicating an effi-
Figure 1
Determination of the efficiency for the standard, reference and clinical samples. The threshold cycle is the cycle
number at which the fluorescence curve for a given sample crosses the user-defined noise band. Log to the concentration for
the reference samples is set as log to arbitrary numbers with four-fold difference as the reference samples are four-fold serial
dilutions. The actual concentration is not needed when determining the efficiency as it depends on the slope of the line only.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
Page 5 of 8
(page number not for citation purposes)
ciency of 2.0. The slope for clinical sample line was not
significantly different from the slope for the standard sam-
ples line (slope for the standard: -3.144 and standard er-
ror: 0.065, t-test: z = 0.54, P = 0.59).
In table 4 slopes and standard errors for dilution series of
negative samples spiked with 103 copies/µl C. pneumoniae
DNA and the two samples (samples no. 1 and 60) with
low C. pneumoniae DNA concentration are shown. Two-
fold dilution series were prepared for each sample. The
slopes for the spiked samples were compared to the slope
of the standard samples from the same run. P-values for a
t-test testing whether slopes differ significantly are shown.
Three (sample no's. 101, 131 and 160) of the 20 samples
have slopes significantly different from the slope of the
corresponding standard and none of these were C. pneu-
moniae positive when not spiked. This means that the effi-
ciency differs significantly and quantification of these
samples is not accurate. It should be noted though, that
for the samples 1, 60 and 133 (the three C. pneumoniae
positive samples) there are no signs of inhibition. There-
fore, quantification of the positive samples is probably
reasonably accurate.
For the remaining 17 samples the slopes were not signifi-
cantly different indicating that the efficiencies should
match satisfyingly between standard samples and spiked
clinical samples. Hence, the PCR conditions seem to be
similar in the clinical and standard samples, therefore de-
tection and quantification is possible. Consequently, it is
probably unlikely that larger numbers of positive samples
were missed because of suboptimal PCR efficiency. If PCR
efficiency is in part influenced by inhibitors, our results
indicate that Chelex release of DNA from nasopharyngeal
aspirates is sufficient in most samples. However, if the na-
sopharyngeal aspirates are contaminated with e.g. blood,
which contain many PCR inhibitors, further purification
might be needed.
It should be noted that even though slopes are not signif-
icantly different, there might still be differences in effi-
ciencies, as the t-test allows for some variation. In table 4
it is also seen that some of the efficiencies are larger than
2, which should not be possible according to PCR theory.
Some of the samples have efficiencies very much larger
than 2 (samples 131 and 160) and these were also found
to differ significantly from efficiencies of the standards.
Substances in the samples that interfere with the PCR
probably cause this. In the samples with efficiency just
slightly higher than 2, it is probably caused by the fact that
the slope is determined by linear regression. The linear re-
gression does not take into account that the slope can
maximally be -3.32, which corresponds to an efficiency of
2.0. Furthermore, it is notable that slopes for the standard
samples vary from -3.266 to -3.716 (E varies from 1.86–
2.01). Many things may cause this variation. First of all,
variations in preparation of the standard dilution series is
difficult to avoid because of pipetting variations, but also
because DNA molecules do not behave like smaller mole-
cules in solution. DNA is a large molecule and it is there-
fore likely to make intramolecular (electrostatic)
interactions and also interactions with other molecules.
These interactions are hard to predict as they depend on
1) which molecules are present and their concentration in
the solution, 2) temperature 3) length and integrity of the
DNA molecules. These phenomena probably contribute
to the variation. This emphasizes that when a quantitative
PCR result is presented it should be interpreted with care
and always in the context of the experimental setup. When
comparing quantitative measures determined in this way,
Figure 2
Effect of difference in efficiency between standard
samples and samples. This figure illustrates the error in
determination of concentration by real-time PCR at cycle no.
30 when the efficiencies differ between standard samples and
samples. Number of cycles: n, Efficiency standard samples:
Estd, efficiency reference samples: Ers, Number of amplicons
at cycle n: Nn, Number of amplicons at cycle zero: N0. When
the two equations are divided by eachother it is seen that
there is an 23-fold underestimation of the concentration
when Estd = 2.0 and Ers = 1.8. From this calculation it is also
evident that at higher cycle number the error in concentra-
tion determination is larger.
 n= 30  
                                   Nn = N0 x 2
30 = N0 x 1.074 x 10
9
Estd = 2.0
                                                  23-fold underestimation at 
                                                  a threshold cycle of 30
n = 30
                                Nn = N0 x 1.8
30 = N0 x 4.552 x 10
7
Ers = 1.8
Table 3: Positive samples found among 136 clinical samples ana-
lysed with PCR methods 1 and 2. *copies/µl is the mean of two 
measurements from two different runs.
Patient sample no. IgM Method 1 
(copies/µl)* Method 2
1 +9 . 7 3+
60 +1 . 0 8+
133 + 750.80 +BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
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it should probably be recommended to run the samples in
the same run, to run at least two replicates to obtain a
mean value or to include internal amplification controls.
Even then the results should be interpreted with care. It is
possible to detect relatively small differences between
sample concentrations with quantitative real-time PCR,
but the exact factor of difference between samples should
be interpreted very cautiously. We have observed this pre-
viously [9] with our standard dilution series; in most runs
it is actually possible to distinguish between e.g. 10 cop-
ies/µl and 5 copies/µl standard samples, but the factor of
difference, if exact quantitative measures are compared,
can vary substantially. Furthermore, the fact that the cross-
ing points determined for the unknown samples are pro-
portional to the log of the concentration and not directly
to the concentration is also a major error factor because
invlog enlarges the errors when concentration is calculat-
ed.
In practice it would not be feasible to test the PCR efficien-
cy for every sample and in every run, because of the added
time and costs. Therefore, it should be done when setting
up a new real-time PCR assay and DNA purification meth-
od for a new clinical sample type. In our opinion, based
on this study, the efficiency can provide a rough estimate
for how well the PCR assay performs in a specific sample
type, but small differences in efficiency should be inter-
preted cautiously because as described above many error
factors are involved in the determination of this parame-
ter.
Analysing replicates could be relevant for nasopharyngeal
aspirates as C. pneumoniae might be present in very low
numbers. The reason could be that cells in the nasopha-
ryngeal aspirates stem from the superficial epithelium and
C. pneumoniae might be present in larger numbers in deep-
er cell layers [13]. The disadvantages of analysing replicate
samples are that it adds extra costs, time and strict control
of contamination. As C. pneumoniae tends to be present in
low numbers especially in non-acute patients as in this
study, it might be more feasible to attempt concentrating
samples before or after DNA extraction [7,14] or to im-
prove sampling methods.
Table 4: Determination of PCR efficiency in 20 spiked clinical samples. S.E.: standard error, Eff.: Efficiency, std. standard samples. For 
each of 20 randomly selected negative samples spiked with C. pneumoniae DNA, the slope was determined as described and the effi-
ciency calculated from the slope. The slope of each sample was compared to the slope of the standard from the same run with a t-test 
and the P-values are shown. Therefore, some of the samples are compared to the same standard.
Sample no. Slope sample S.E. sample Eff. sample Slope std. S.E. std. Eff. std. P-value*
1 -3.064 0.215 2.12 -3.406 0.232 1.97 0.28
60 -3.190 0.273 2.06 0.55
14 -2.873 0.147 2.23 -3.266 0.264 2.02 0.19
31 -3.222 0.091 2.04 -3.623 0.340 1.89 0.25
32 -3.549 0.156 1.91 0.84
78 -3.328 0.153 2.00 0.43
84 -4.318 0.512 1.70 -3.321 0.180 2.00 0.066
90 -3.379 0.177 1.98 0.82
97 -3.503 0.291 1.93 -3.716 0.187 1.86 0.54
101 -3.266 0.085 2.02 0.028
103 -3.388 0.091 1.97 0.12
118 -3.398 0.189 1.97 -3.492 0.094 1.93 0.65
127 -3.495 0.145 1.93 0.99
131 -2.809 0.108 2.27 0.00
138 -3.545 0.183 1.91 -3.300 0.101 2.01 0.24
145 -3.396 0.134 1.97 0.28
150 -3.652 0.394 1.88 0.39
159 -3.491 0.133 1.93 -3.615 0.056 1.89 0.39
160 -2.135 0.313 2.94 0.00
171 -3.531 0.088 1.92 0.42BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
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Conclusions
In this study sensitivity and clinical performance seems to
be the same for conventional PCR and real-time PCR, but
this needs to be confirmed by analysis of more clinical
samples. We extended the investigation of clinical per-
formance with determination of the PCR efficiency in the
samples. The efficiencies determined by real-time PCR in
clinical samples were in 17/20 cases determined not to be
significantly different from efficiencies of the standards.
This means that suboptimal PCR efficiency was probably
not the explanation for the low positivity rate of C. pneu-
moniae in the nasopharyngeal aspirates. The efficiency
may be used as a rough estimate for how well real-time




Real-time quantitative PCR was performed in a Lightcycler
instrument as described previously [9]. Briefly, the real-
time PCR amplifies a 140 bp PCR product from the pmp4
gene of C. pneumoniae. The PCR fragment is detected with
a fluorescent probe set using fluorescence resonance ener-
gy transfer. The pmp4 gene encodes a membrane protein
from the polymorphic membrane protein (Pmp) family,
which contain 21 proteins [15]. Each gene is present in
one copy on the genome, homologs are found in C. psit-
taci and C. trachomatis, but the sequences are not very sim-
ilar on DNA level, therefore it is possible to design species
specific primers and probes. Specificity was assessed by
database searches with the primer and probe sequences
and pmp4 gene sequences were compared for the known
genome sequences of C. pneumoniae. Primer and probe se-
quences were found to be specific for C. pneumoniae and
the  pmp4 gene sequences for the known isolates were
identical [9]. Real-time PCR was performed in 20 µl con-
sisting of: 0.5 µm of each primer, 0.2 µm of each probe, 5
mM MgCl2, 2.0 µl Faststart DNA Master Hybridisation
Probes (Roche) and 2 or 6.8 µl template. The mixture was
loaded into glass capillary tubes and cycling performed as
previously described [9] The PCR was performed with 6.8
µl template DNA for analysis of the reference samples and
2 µl for analysis of the clinical samples and standard sam-
ples (see below for definition of samples). For easy com-
parison sample volumes are shown in table 1.
Standard samples
C. pneumoniae EB was purified by gradient centrifugation
as previously described [16] and genomic DNA was puri-
fied with the Genomic-tip system from Qiagen following
instructions from the manufacturer. DNA concentration
and purity were analysed by agarose gel electrophoresis
and measurement of OD at 260 and 280 nm. A ten-fold
standard dilution series of purified C. pneumoniae genom-
ic DNA with known concentration was used for quantifi-
cation, concentrations ranged between 105 and 1 copies/
µl [9]. The Lightcycler software determined the threshold
cycles for the standard samples and a standard curve was
generated. The threshold cycle for unknown samples was
determined for two replicates and concentrations were
calculated from the standard curve also using the Lightcy-
cler software. A negative control containing all reagents
except template DNA was included in all runs. A sample
was considered to be positive when the fluorescence curve
was sigmoidal and reached fluorescence levels above the
fluorescence threshold set in the Ligthcycler software dur-
ing analysis.
Method 2
A multiplex PCR with three primer sets was used which
amplify fragments from the 16S rRNA gene of the three
Chlamydia species. The primer pair specific for C. trachom-
atis, which amplifies a 240 bp product, was designed by
Pollard et al. [17], from these primers analogues were de-
signed for the other Chlamydia species [11]. An internal
amplification control was included in order to detect inhi-
bition or suboptimal reaction conditions [11,17,18]. Am-
plicons were visualised with ethidium bromide and
agarose gel electrophoresis. Positive results were con-
firmed with a C. pneumoniae specific PCR with primers de-
tecting a 463 bp fragment of the 16S rDNA [19]. For
analysis of the reference samples 10 µl template DNA was
used. For analysis of the clinical samples 10 µl was used.
If inhibition occurred, the assay was repeated with 5 µl or
2 µl of the sample. Samples volumes are shown in table 1
for both PCR methods.
For both PCR methods precautions were taken to avoid
contamination. Filter pipette tips were used and reagents
were mixed in rooms separated from rooms where C.
pneumoniae DNA from culturing, DNA purification etc.
was present.
Reference samples
C. pneumoniae was cultivated in HeLa cells as previously
described [20]. Cells were scraped off with a rubber po-
liceman, centrifuged and resuspended in TE-buffer. Pro-
teinase K was added and the mixture was incubated for
one hour at 55°C. Proteinase K was inactivated by incuba-
tion at 95°C for 10 min. A serial four-fold dilution series
was prepared in TE-buffer with 10 dilutions ensuring a
wide range of concentrations. Samples with C. pneumoniae
DNA concentrations near the detection limit should
therefore be present for the methods tested. In addition,
two negative controls containing TE-buffer only were in-
cluded. The two PCR methods were tested on the refer-
ence samples and their relative sensitivities were obtained.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/17
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Clinical samples and spiked clinical samples for efficiency 
determination
Clinical samples
Nasopharyngeal aspirates were previously obtained from
patients with chronic cough from the Dept. of Pulmonary
Medicine at Aarhus University Hospital, Denmark. Inclu-
sion criteria were age >15 yrs., a cough period of 2–12
weeks, a normal chest radiograph, normal spirometry and
absence of chronic cardiopulmonary disease [10]. For this
study a selection of 136 samples was used. DNA was re-
leased from the nasopharyngeal aspirates by vortexing
with 20% w/v Chelex 100 slurry followed by boiling of
the suspensions for 10 min; then centrifuged at 20,000 ×
g for 10 min. [10]. Chelex-100 is an ion-exchange resin
that scavenges multivalent metal ions. PCR methods 1
and 2 were tested on these samples.
Spiked clinical samples
The real-time PCR was used for determination of PCR ef-
ficiency in a selection of clinical samples in the following
way. For negative samples and samples with low C. pneu-
moniae DNA concentration spiking with 103 copies/µl C.
pneumoniae was done. Afterwards a 2-fold dilution series
with 8 dilutions was done in water with 10 µg/ml yeast
RNA as carrier nucleic acid [9]. For each of the dilutions
we measured threshold cycles and plotted them towards
log to relative concentrations of the dilutions. The slope
was determined and compared to the slope of the stand-
ard samples from the same run.
Authors' contributions
Author T.M. carried out the real-time PCR experiments
and the statistical analysis of the data and drafted the
manuscript. Author S.B. participated in design and coor-
dination of the study. Author N.H.B collected the clinical
samples. Author L.Ø. participated in design and coordina-
tion of the study and provided reference samples. Author
J.S.J. carried out the conventional PCR experiments. Au-
thor G. C. participated in design and coordination of the
study.
Acknowledgements
The Danish Medical Research Council supported the research (grants no. 
9900750 and 9700659). We thank Inger Andersen, Karin Skovgaard Sø-
rensen, Birthe Dohn and Jonna Guldberg for technical assistance and Lisbet 
Wellejus Pedersen for linguistic assistance
References
1. Grayston JT: Infections caused by Chlamydia pneumoniae
strain TWAR. Clin Infect Dis 1992, 15(5):757-761
2. Peeling RW, Brunham RC: Chlamydiae as pathogens: new spe-
cies and new issues. Emerg Infect Dis 1996, 2(4):307-319
3. Saikku P: Chlamydia pneumoniae in atherosclerosis. J Intern Med
2000, 247(3):391-396
4. Dowell SF, Peeling RW, Boman J, Carlone GM, Fields BS, Guarner J,
Hammerschlag MR, Jackson LA, Kuo CC, Maass M, Messmer TO,
Talkington DF, Tondella ML, Zaki SR: C. pneumoniae Workshop
Participants. Standardizing Chlamydia pneumoniae assays:
recommendations from the Centers for Disease Control and
Prevention (USA) and the Laboratory Centre for Disease
Control (Canada). Clin Infect Dis 2001, 33(4):492-503
5. Mahony JB, Chong S, Coombes BK, Smieja M, Petrich A: Analytical
sensitivity, reproducibility of results, and clinical perform-
ance of five PCR assays for detecting Chlamydia pneumoniae
DNA in peripheral blood mononuclear cells. J Clin Microbiol
2000, 38(7):2622-2627
6. Apfalter P, Blasi F, Boman J, Gaydos CA, Kundi M, Maass M, Makris-
tathis A, Meijer A, Nadrchal R, Persson K, Rotter ML, Tong CY,
Stanek G, Hirschlm AM: Multicenter Comparison Trial of DNA
Extraction Methods and PCR Assays for Detection of
Chlamydia pneumoniae in Endarterectomy Specimens. J Clin
Microbiol 2001, 39(2):519-524
7. Smieja M, Mahony JB, Goldsmith CH, Chong S, Petrich A, Chernesky
M: Replicate PCR Testing and Probit Analysis for Detection
and Quantitation of Chlamydia pneumoniae in Clinical Speci-
mens. J Clin Microbiol 2001, 39(5):1796-1801
8. Boman J, Gaydos CA, Quinn TC: Molecular diagnosis of Chlamy-
dia pneumoniae infection. J Clin Microbiol 1999, 37(12):3791-3799
9. Mygind T, Birkelund S, Falk E, Christiansen G: Evaluation of real-
time quantitative PCR for identification and quantification of
Chlamydia pneumoniae by comparison with immunohisto-
chemistry. J Microbiol Meth 2001, 46:241-251
10. Birkebæk NH, Jensen JS, Seefeldt T, Degn J, Huniche B, Andersen PL,
Østergaard L: Chlamydia pneumoniae infection in adults with
chronic cough compared with healthy blood donors.  Eur
Respir J 2000, 16(1):108-111
11. Storgaard M, Østergaard L, Jensen JS, Farholt S, Larsen K, Ovesen T,
Nødgaard H, Andersen PL: Chlamydia pneumoniae in children
with otitis media. Clin Infect Dis 1997, 25(5):1090-1093
12. Belotserkovskii BP, Johnston BH: Denaturation and association
of DNA sequences by certain polypropylene surfaces. Anal Bi-
ochem 1997, 251(2):251-262
13. Kauppinen M, Saikku P: Pneumonia due to Chlamydia pneumoni-
ae: prevalence, clinical features, diagnosis, and treatment.
Clin Infect Dis 1995, 21(Suppl. 3):S244-S252
14. Maass M, Jahn J, Gieffers J, Dalhoff K, Katus HA, Solbach W: Detec-
tion of Chlamydia pneumoniae within peripheral blood mono-
cytes of patients with unstable angina or myocardial
infarction. J Infect Dis 2000, 181(Suppl 3):S449-S451
15. Kalman S, Mitchell W, Marathe R, Lammel C, Fan J, Hyman RW, Ol-
inger L, Grimwood J, Davis RW, Stephens RS: Comparative ge-
nomes of Chlamydia pneumoniae and C. trachomatis. Nat Genet
1999, 21(4):385-389
16. Knudsen K, Madsen AS, Mygind P, Christiansen G, Birkelund S: Iden-
tification of two novel genes encoding 97- to 99-kilodalton
outer membrane proteins of Chlamydia pneumoniae. Infect Im-
mun 1999, 67(1):375-383
17. Pollard DR, Tyler SD, Ng CW, Rozee KR: A polymerase chain re-
action (PCR) protocol for the specific detection of Chlamy-
dia spp. Mol Cell Probes 1989, 3(4):383-389
18. Tarp B, Jensen JS, Østergaard L, Andersen PL: Search for agents
causing atypical pneumonia in HIV-positive patients by in-
hibitor-controlled PCR assays. Eur Respir J 1999, 13(1):175-179
19. Gaydos CA, Quinn TC, Eiden JJ: Identification of Chlamydia pneu-
moniae by DNA amplification of the 16S rRNA gene. J Clin
Microbiol 1992, 30(4):796-800
20. Clausen JD, Christiansen G, Holst HU, Birkelund S: Chlamydia tra-
chomatis utilizes the host cell microtubule network during
early events of infection. Mol Microbiol 1997, 25(3):441-449